NCT01795872View on ClinicalTrials.gov

Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions
Multiple Sclerosis
Interventions
PROCEDURE

Several diagnostic procedures

No drug will be assigned, diagnostic assessment within the study.

Trial Locations (77)

1076

Budapest

1145

Budapest

1200

Bruxelles - Brussel

1525

Ljubljana

3000

Leuven

3010

Bern

4000

Liège

4012

Debrecen

4031

Basel

5021

Bergen

6020

Innsbruck

6720

Szeged

8036

Graz

9000

Ghent

9007

Sankt Gallen

10043

Orbassano

10126

Torino

16761

Hennigsdorf

17475

Greifswald

20100

Turku

20132

Milan

21013

Gallarate

21033

Dijon

27100

Pavia

28040

Madrid

29010

Málaga

31059

Toulouse

33000

Bordeaux

33521

Tampere

35033

Rennes

35039

Marburg

35128

Padua

35392

Giessen

37099

Göttingen

40225

Düsseldorf

41071

Seville

46026

Valencia

48149

Münster

50420

Wroclaw

50931

Cologne

55101

Mainz

59037

Lille

63003

Clermont-Ferrand

63069

Offenbach

81377

München

89075

Ulm

90029

Oulu

93053

Regensburg

97080

Würzburg

99089

Erfurt

5262000

Tel Litwinsky

T2N 2T9

Calgary

N6A 5A5

London

K1H 8L6

Ottawa

H2L 4M1

Montreal

625 00

Brno

500 05

Hradec Králové

708 52

Ostrava-Poruba

121 11

Prague

DK-2600

Glostrup Municipality

Unknown

Seinäjoki

Jerusalem

06200

Nice

06120

Halle

6131 BK

Sittard

85-681

Bydgoszcz

30-503

Krakow

90-153

Lodz

20-090

Lublin

3030-075

Coimbra

08035

Barcelona

08036

Barcelona

08907

L'Hospitalet de Llobregat

413 45

Gothenburg

S10 2JF

Sheffield

AB25 2ZN

Aberdeen

DD1 9SY

Dundee

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01795872 - Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis | Biotech Hunter | Biotech Hunter